Time delay toxin activation
 | This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (June 2015) |
Time Delay Toxin Activation (TDTA) belongs to a class of chemotherapy drugs known as High Specificity Anticancer Agents. This is a process for manufacturing and administering chemotherapy drugs in a nontoxic, proto-drug form. Then, after a time delay to allow for concentration in the target cancer or invasive tissues or cells, the non-toxic drug is then modified by an activation drug to selectively provide toxic levels of a pharmacologically active agent to the target issue. This minimizes the toxicity to healthy cells, reducing the adverse side-effects of chemotherapy.
This idea was first proposed by Dr. Evan Harris Walker in 1980.
References
- "US Patent Office application number 20040192578". Retrieved February 2, 2006.
- "High specificity anticancer agents". USPTO Full text patent database. Retrieved January 29, 2006.
 | This oncology article is a stub. You can help Wikipedia by expanding it. |